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Abstract
Background and purpose: Despite the view that only b2- as opposed to b1-adrenoceptors (bARs) couple to Gi, some data
indicate that the b1AR-evoked inotropic response is also influenced by the inhibition of Gi. Therefore, we wanted to
determine if Gi exerts tonic receptor-independent inhibition upon basal adenylyl cyclase (AC) activity in cardiomyocytes.
Experimental approach: We used the Gs-selective (R,R)- and the Gs- and Gi-activating (R,S)-fenoterol to selectively activate
b2ARs (b1AR blockade present) in combination with Gi inactivation with pertussis toxin (PTX). We also determined the effect
of PTX upon basal and forskolin-mediated responses. Contractility was measured ex vivo in left ventricular strips and cAMP
accumulation was measured in isolated ventricular cardiomyocytes from adult Wistar rats.
Key results: PTX amplified both the (R,R)- and (R,S)-fenoterol-evoked maximal inotropic response and concentration-
dependent increases in cAMP accumulation. The EC50 values of fenoterol matched published binding affinities. The PTX
enhancement of the Gs-selective (R,R)-fenoterol-mediated responses suggests that Gi regulates AC activity independent of
receptor coupling to Gi protein. Consistent with this hypothesis, forskolin-evoked cAMP accumulation was increased and
inotropic responses to forskolin were potentiated by PTX treatment. In non-PTX-treated tissue, phosphodiesterase (PDE) 3
and 4 inhibition or removal of either constitutive muscarinic receptor activation of Gi with atropine or removal of
constitutive adenosine receptor activation with CGS 15943 had no effect upon contractility. However, in PTX-treated tissue,
PDE3 and 4 inhibition alone increased basal levels of cAMP and accordingly evoked a large inotropic response.
Conclusions and implications: Together, these data indicate that Gi exerts intrinsic receptor-independent inhibitory activity
upon AC. We propose that PTX treatment shifts the balance of intrinsic Gi and Gs activity upon AC towards Gs, enhancing
the effect of all cAMP-mediated inotropic agents.
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Introduction
According to conventional understanding, G proteins transduce
signals from activated G protein-coupled receptors (GPCRs) via
second messengers to regulate numerous downstream signalling
targets in the cell [1,2]. G proteins are found on the cytoplasmic
side of the plasma membrane, composed of a guanine nucleotide
binding a subunit (Ga) and a bc dimer (Gbc). Upon GPCR
activation, GDP is exchanged for GTP on Ga, and both the GTP-
liganded Ga and the Gbc dimer regulate downstream targets. Five
subfamilies of Ga have been classified, whereof Gai/o is the only
one able to inhibit adenylyl cyclase (AC) and the production of
cAMP [3].
The predominant Gi-coupled receptor in the heart ventricle is
the M2 muscarinic acetylcholine receptor [4]. Constitutive activity
of this receptor exerts a mild, continuous inhibition of AC activity
in normal rat ventricular cardiomyocyte membranes [5–7]. It is
well established that the muscarinic system also antagonizes the
inotropic responses mediated by b-adrenoceptors (bARs) [4],
known as accentuated antagonism [8,9].
The major stimulatory input in the myocardium comes from the
b1- and b2ARs, whereby activation of these receptors leads to
positive inotropic responses. In 1995, Xiao et al. made the
intriguing observation that pertussis toxin (PTX), known to cause
ADP-ribosylation of the Gai subunit, uncoupling the GPCRs from
Gi, enhanced b2AR- but not b1AR-mediated positive inotropic
responses in isolated rat cardiomyocytes [10]. Together with
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subsequent studies [11–14], it has been widely accepted that in
addition to Gs, the b2ARs also couple to Gi in native systems while
the b1ARs do not.
However, we recently reported that the isoproterenol-mediated
inotropic response in left ventricular muscle strips was potentiated
by PTX [15]. When examined separately, both the b1- and b2AR-
mediated inotropic response (bAR-IR) and cAMP accumulation in
isolated ventricular cardiomyocytes were increased by PTX pre-
treatment [16]. Additional data from rat [17], guinea-pig [18] and
normal [19] as well as transgenic mice overexpressing the b2AR
[20] indicate that b1AR-evoked contractility in the heart may also
be regulated by Gi activity. Due to conflicting data on the role of
Gi in b1AR signalling, we wanted to further investigate this issue.
It has previously been reported that AC activity evoked by
forskolin and agonists at Gs-coupled receptors can be increased by
prior PTX treatment in various cell types [21–24], as well as in
cardiomyocytes [25] and sarcolemmal membranes from failing
human myocardium [26]. However, these studies did not take into
account the presence of constitutively active GPCRs which are
known to regulate basal AC activity [7,27]. It has been suggested
by El-Armouche et al. [28], and shown by Rau et al. [17] through
overexpression of Gai2 as well as by Hussain et al. [15] by the use
of phosphodiesterase (PDE) 3 and 4 inhibitors that Gi may have
receptor-independent effects, whereby it directly inhibits AC
activity. We examined the possibility that Gi may have receptor-
independent effects in the absence of constitutively active receptors
by using the unique properties exhibited by stereoisomers of the
b2AR agonist fenoterol. (R,R)-fenoterol was first characterized by
Woo et al. (2009) to selectively activate only the Gs pathway of the
b2AR, whereas the other stereoisomers, including (R,S) used in
this study, activate both the Gs and Gi pathways [29]. On this
basis, (R,R)-fenoterol has been used as a tool to differentiate Gs-
and Gi-coupling of the b2AR [30]. We further studied receptor-
independent effects of Gi by using the direct AC activator
forskolin, as well as the effects of PDE3 and 4 inhibition in the
absence and presence of known antagonists or inverse agonists.
Our data indicate that in addition to the traditional role of Gi in
receptor signalling, this G protein exerts a constant intrinsic
inhibition upon AC independent of receptor activation.
Methods
Animal care
Experiments and animal care were conducted in accordance
with the European Convention for the protection of vertebrate
animals used for experimental and other scientific purposes
(Council of Europe no. 123, Strasbourg 1985) and approved by
the Norwegian Animal Research Authority. The animals were
housed with a 12/12 h cycle at 21uC, food and water available ad
libitum.
Measurement of contractility in left ventricular strips
Left ventricular strips (diameter ,1.0 mm) were prepared from
male Wistar rats (Taconic, Skensved, Denmark) weighing 300–
350 g, mounted in 31uC organ baths containing physiological salt
solution with 1.8 mM Ca2+, equilibrated and field-stimulated at
1 Hz [31,32]. Contraction-relaxation cycles were recorded and
analysed as previously described [33,34]. Maximal development of
force (dF/dt)max was measured and inotropic responses were
expressed as increase in (dF/dt)max. Concentration-response
curves were constructed by estimating centiles (EC10 to EC100)
and calculating the corresponding means, and the horizontal
positioning is expressed as –logEC50 values [33].
In a subset of rats, PTX was administered at a dose of 60 mg/kg
i.p. as a single injection three days prior to isolation of the left
ventricular muscle strips. Control rats were given a saline injection
of equal volume. Data from animals treated with PTX were only
included if carbachol inhibition of the bAR-IR was completely
abolished (Fig. 1B). To confirm the effectiveness of PTX treatment
in vivo (subset of 6 PTX-treated rats and 7 saline-treated rats) and
in cardiomyocytes (see below), we measured the level of PTX-
catalysed incorporation of [32P]ADP-ribose from [32P]NAD into
available Gi as previously described [15].
Measurement of cAMP accumulation in left ventricular
cardiomyocytes
Adult left ventricular cardiomyocytes were isolated from excised
male Wistar rat hearts by retrograde aortic perfusion with a
nominally Ca2+-free JOKLIK-MEM solution and enzymatic
digestion using collagenase (90 U/mL) as previously described
[35]. Left ventricular cardiomyocytes were incubated for 20 h in the
absence or presence of 1 mg/ml PTX (1.2 ml reaction volume).
Experiments were conducted in the presence of the b1AR blocker
CGP20712 (300 nM), the non-selective PDE inhibitor IBMX
(0.5 mM) or PDE3 and 4 inhibitors cilostamide (1 mM) and
rolipram (10 mM), as indicated. cAMP accumulation was measured
by radioimmunoassay as previously described [36]. Protein was
measured with the Coomassie Plus Protein Assay (Pierce, Rockford,
IL) according to the manufacturer’s protocol and cAMP accumu-
lation was normalized to the amount of protein in each sample.
Measurement of (R,R)- and (R,S)-fenoterol-mediated
inotropic responses and ability to activate adenylyl
cyclase
To evaluate the b2AR-mediated inotropic response, Gs-selective
(R,R)-fenoterol and Gs- and Gi-activating (R,S)-fenoterol were
assessed by conducting a concentration-response experiment in the
presence of a selective b1AR antagonist (300 nM CGP20712).
Likewise, (R,R)- and (R,S)-mediated activation of AC was assessed
by incubating cardiomyocytes for 10 min with increasing concen-
trations of either stereoisomer (0–100 mM) in the presence of
300 nM CGP20712. All cAMP accumulation experiments in this
subset were conducted in the presence of the non-selective PDE
inhibitor IBMX (0.5 mM).
Measurement of spontaneous intrinsic Gi inhibition upon
adenylyl cyclase activity
Receptor-independent Gi activity was assessed through forskolin
concentration-response curves (50 nM-10 mM) in left ventricular
strips and isolated cardiomyocytes in the presence of the non-
selective bAR antagonist timolol (1 mM) and a1-adrenoceptor
antagonist prazosin (0.1 mM, ventricular strips only) with and
without prior pre-treatment with PTX (as described above). To
determine if spontaneous intrinsic activity of Gi regulated basal AC
activity, the inotropic response in ventricular strips or cAMP
accumulation in cardiomyocytes pre-treated with or without PTX
was measured in the presence of both the PDE3 inhibitor cilostamide
(1 mM) and PDE4 inhibitor rolipram (10 mM) in the presence of the
non-selective bAR antagonist timolol (1 mM) and a1-adrenoceptor
antagonist prazosin (0.1 mM, ventricular strips only).
Statistics
Data are expressed as mean 6 SEM from n animals. p,0.05
was considered statistically significant (One-way ANOVA and
student’s t-test). When appropriate, Bonferroni corrections were
made to control for multiple comparisons.
Receptor-Independent Gi Regulation of AC
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Drugs and solutions
Prazosin hydrochloride, (-)isoprenaline hydrochloride, timolol
maleate, atropine sulphate, lidocaine (2-diethylamino-N-[2,6-
dimethylphenyl]-acetamide) hydrochloride, L-ascorbic acid and
3-isobutyl-1-methylxanthine (IBMX) were purchased from
Sigma-Aldrich (St. Louis, MO, USA). CGP20712 dihydrochlo-
ride, CGS 15943, cilostamide and rolipram were purchased from
Tocris Bioscience (Bristol, UK). Forskolin was from LC Labora-
tories (Woburn, MA, USA). (R,R)- and (R,S)-fenoterol were a kind
gift from J. Kozocas (SRI International, Menlo Park, CA, USA).
Figure 1. Effect of PTX upon (R,R)- and (R,S)-fenoterol-induced cAMP accumulation. (A) Representative autoradiogram showing ADP-
ribosylated Gai protein levels in rat ventricle pre-treated with saline (control) or PTX. (B) Representative traces showing inotropic responses (mN)
evoked by forskolin (FSK) and the subsequent effect of carbachol (Cch) and reversal of carbachol effects by atropine in left ventricular strips from rats
pre-treated with saline (Control; top) or with PTX (bottom). Drug concentrations are given in -Log(M). (C) Concentration-response curves to (R,R)- and
(R,S)-fenoterol-mediated cAMP accumulation in isolated ventricular cardiomyocytes in the presence of IBMX and the b1AR antagonist CGP20712
(300 nM) in control or after PTX pre-treatment. Data are mean 6 SEM. Basal cAMP accumulation was (in pmol cAMP/mg protein): (R,R-series) control:
18.562.8; PTX: 19.763.2; (R,S-series) control 11.962.5; PTX 16.762.0. RR: (R,R)-fenoterol; RS: (R,S)-fenoterol; *P,0.05, paired t-test.
doi:10.1371/journal.pone.0106608.g001
Receptor-Independent Gi Regulation of AC
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Isoflurane (1-chloro-2,2,2-trifluoroethyl difluoromethyl ether;
Forene) was from Abbot Scandinavia (Solna, Sweden). Pertussis
toxin was from Merck chemicals (Nottingham, UK). [3H]cAMP
was from PerkinElmer (Boston, MA, USA).
Results
Gi was essentially inactivated by pertussis toxin
The effectiveness of in vivo PTX treatment to inhibit Gi was
assessed by measuring PTX-catalysed incorporation of [32P]ADP-
ribose from [32P]NAD into available Gi in ventricular tissue. An
,80-90% reduction was seen in the ability of subsequent PTX to
ADP-ribosylate Gi in vitro in animals pre-treated with PTX
compared to animals given saline injection (PTX-treated n= 6,
saline-treated control n = 7, see Fig. 1A). It was not possible to
distinguish the different Gai isoforms in the autoradiogram due to
the similarity in size (39-41 kDa). Importantly, in the PTX-treated
group, data were included only if carbachol-induced inhibition of
the bAR-IR was abolished (Fig. 1B). In the (R,R)- and (R,S)-
fenoterol study, 83% of the PTX-treated rats were included in the
study. In the forskolin and PDE inhibitor study 88% of the rats
met the criteria and were included.
(R,R)- and (R,S)-fenoterol-stimulated cAMP accumulation
was amplified after inactivation of Gi
(R,R)- and (R,S)-fenoterol-induced AC activation was assessed
by measuring cAMP accumulation in isolated left ventricular
cardiomyocytes in the presence of the non-selective PDE inhibitor
IBMX. Surprisingly, PTX inactivation of Gi amplified the
concentration-response curve to Gs-selective (R,R)-fenoterol
(Fig. 1C). (R,R)-fenoterol selectively activated the b2AR at the
concentration range 10 nM-3 mM, after which it overcame b1AR
blockade by CGP20712 (not shown). Maximal cAMP accumula-
tion evoked by 3 mM (R,R)-fenoterol was enhanced by 60% from
55 pmol/mg protein in control to 92 pmol/mg protein in the
presence of PTX. The EC50 was not significantly different after
PTX treatment (140648 nM in control and 245622 nM after
PTX treatment) (Fig. 1C). These EC50 values were similar to the
previously published binding affinity of (R,R)-fenoterol at the
b2AR (350 6 30 nM [37]).
As expected, (R,S)-fenoterol concentration-response curves were
similarly modified by PTX treatment. Maximal cAMP accumu-
lation evoked by the highest selective concentration of (R,S)-
fenoterol for the b2AR (100 mM) was enhanced by 62% from
38 pmol/mg protein in control to 61 pmol/mg protein in the
presence of PTX. The EC50 value was not significantly shifted
from 3.560.5 mM in control to 5.060.9 mM after PTX treatment
(Fig. 1C). Again, these EC50 values were similar to the published
binding affinity of (R,S)-fenoterol of 3.7 6 0.3 mM [37]. Together,
these data demonstrate that PTX amplifies the amount of cAMP
produced by both stereoisomers, despite dissimilar G protein-
coupling profiles. This suggests that Gi exerts inhibitory activity
upon AC downstream of receptor coupling to G protein.
Maximal inotropic responses to both (R,R)- and
(R,S)-fenoterol were amplified by Gi inactivation or PDE
inhibition
In untreated (control) left ventricular muscle strips, the highest
concentration given of (R,R)- and (R,S)-fenoterol elicited very
small inotropic responses of 8.662.7% and 4.462.9% above
basal, respectively (b1AR antagonist CGP20712 present; Fig. 2A).
These values were slightly lower than inotropic responses obtained
by b2AR stimulation by adrenaline in the presence of CGP20712
(,11% above basal, data not shown).
The inotropic responses evoked by maximal concentrations of
both (R,R)- and (R,S)-fenoterol were significantly amplified by
either PTX pre-treatment (4466% or 2264% above basal,
respectively) or PDE3 and 4 inhibition (96611% or 122619%
above basal, respectively) (Fig. 2A). These data are consistent with
the cAMP accumulation data and reinforce the hypothesis that Gi
may have downstream effects independent of receptor activation
in a physiological model using intact, isometrically contracting
ventricular muscle. Further, the data reflect that increased cAMP
accumulation translates to an increased inotropic response.
Figure 2. Effect of PTX and PDE3 and 4 inhibition upon the
inotropic response to (R,R)- and (R,S)-fenoterol stimulation.
Maximal inotropic response (A) and concentration-response curves (B)
to (R,R)- or (R,S)-fenoterol in left ventricular strips from saline-treated
rats (control) or PTX-treated rats or strips from saline-treated rats given
PDE3 (cilostamide, Cil, 1 mM) and PDE4 (rolipram, Rol, 10 mM) inhibitors.
All experiments were conducted in the presence of the b1AR blocker
CGP20712 (300 nM). Inotropic responses are expressed as (dF/dt)max as
percent above basal. Basal force was (in mN/mm2) (R,R) control:
4.360.4; (R,S) control: 4.260.6; (R,R) PTX: 3.560.5; (R,S) PTX: 3.560.4;
(R,R) with Cil/Rol: 3.660.3; (R,S) with Cil/Rol: 3.960.4. Data are mean 6
SEM. RR: (R,R)-fenoterol; RS: (R,S)-fenoterol; *P,0.05 vs. control, One-
way ANOVA with Bonferroni adjustment for multiple comparisons.
**P,0.05 vs. (R,S) with Cil/Rol, One-way ANOVA with Bonferroni
adjustment for multiple comparisons.
doi:10.1371/journal.pone.0106608.g002
Receptor-Independent Gi Regulation of AC
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In the absence of PTX treatment or PDE inhibition it was not
possible to determine the EC50 values for either fenoterol isoform,
due to the very small inotropic response. However, in the presence
of PTX, the EC50 of (R,R)-fenoterol was 139618 nM and of
(R,S)-fenoterol 4.160.4 mM (Fig. 2B), very similar to that obtained
from cAMP accumulation (Fig. 1C) and corresponding to the
affinity values reported in the literature [37]. PDE3 and 4
inhibition shifted the concentration-response curves of both
stereoisomers to lower concentrations (EC50: 58616 nM for
(R,R)- and 0.4460.01 mM for (R,S)-fenoterol), indicating that
both Gi and PDE3 and 4 regulate translation of the cAMP signal
to a functional inotropic response.
Forskolin responses are enhanced by inactivation of Gi
Forskolin, a direct activator of AC, was used to study receptor-
independent effects of Gi on AC activity. To eliminate the
influence of constitutive bAR activation of Gs (known to enhance
forskolin responses), all experiments were conducted in the
presence of the bAR inverse agonist timolol. cAMP accumulation
in response to the maximum concentration of forskolin tested
(10 mM; this concentration was sufficient to reach an asymptotic
response) was enhanced by 85% by PTX treatment from
269641 pmol/mg protein in control to 498669 pmol/mg protein
in the presence of PTX (Fig. 3A).
In control left ventricular strips, forskolin (10 mM) evoked an
inotropic response 120615% above basal with an EC50 of
2.2 mM. After pre-treatment with PTX, the response to forskolin
was significantly shifted to 10-fold lower concentrations, yielding
an EC50 of 0.22 mM, with no change in the maximum inotropic
response (103620% above basal) at maximal tested concentrations
(asymptote reached in range from 1–10 mM, Fig. 3B). Together,
these data demonstrate that forskolin-stimulated AC activity and
functional response in the absence of G protein-coupled receptor
activation is modified by PTX treatment.
Simultaneous inactivation of PDE3 and PDE4 produced a
robust cAMP-dependent inotropic response in
myocardium only after prior inactivation of Gi
The following experiments were conducted in the presence of
bAR blockade (timolol, 1 mM), to eliminate a possible effect of
residual endogenous noradrenaline or constitutive activation of Gs
through b1- or b2ARs. As previously reported [15], and replicated
in this study, concomitant PDE3 and PDE4 inhibition (1 mM
cilostamide and 10 mM rolipram) was sufficient to elicit a large
inotropic response in ventricular strips (77614% above basal) after
PTX treatment (Fig. 4A,C right trace). However, simultaneous
inhibition of PDE3 and 4 did not cause an inotropic effect in
control hearts (0.4260.19% above basal) (Fig. 4A,C left trace),
indicating the absence of constitutively active Gs-coupled recep-
tors. To test whether the effect of PTX occurred as a result of
removing constitutive receptor activation of Gi, we evaluated the
effect of two established Gi-coupled receptor systems in the heart.
Neither the muscarinic inverse agonist atropine (1 mM) nor the
non-selective adenosine inverse agonist CGS 15943 (1 mM), shown
to be an inverse agonist at the Gi-coupled A1 adenosine receptor
[38], alone or in combination evoked a change in contractile force
above basal (Fig. S1).
To investigate the relationship between cAMP and the inotropic
response evoked by PDE3 and 4 inhibition after PTX treatment,
cAMP accumulation was measured in isolated ventricular
cardiomyocytes with or without PTX pre-treatment (Fig. 4B).
Simultaneous inhibition of PDE3 and 4 increased cAMP levels in
control cardiomyocytes (5.560.8 pmol/mg protein above basal).
The level of cAMP accumulation evoked by simultaneous
inhibition of PDE3 and 4 was significantly increased (,2-fold) in
cardiomyocytes pre-treated with PTX (to 12.761.3 pmol/mg
protein above basal, Fig. 4B). The effect of PTX was not due to
removal of constitutively active Gi-coupled receptors, since neither
atropine (1 mM) nor CGS 15943 (1 mM) alone or in combination
in the presence of simultaneous inhibition of PDE3 and 4
mimicked the effect of PTX treatment (Fig. 4B).
Discussion and Conclusions
Data from this study indicate that Gi tonically inhibits basal
cAMP production, limiting functional responses. This inhibition
appears to be independent of constitutive receptor activation of Gs
and Gi upon AC. In support, (1) PTX treatment increased
responses evoked by both the Gs-selective (R,R)- and the dually
Figure 3. Effect of PTX upon the forskolin-evoked cAMP
accumulation and inotropic response. Concentration-response
curves of forskolin-evoked cAMP accumulation in ventricular cardiomy-
ocytes (A) and the inotropic response in ventricular strips (B) in the
presence of the bAR blocker timolol (1 mM) in control or after PTX pre-
treatment. Accumulation of cAMP was measured in the presence of
IBMX, with basal cAMP accumulation (in pmol cAMP/mg protein):
control: 38.865.3; PTX: 30.464.0. Basal force was (in mN/mm2): control:
4.0560.56; PTX: 3.9160.66. Data are mean 6 SEM. *P,0.05, paired
t-test (cAMP accumulation) or unpaired t-test (inotropic response).
doi:10.1371/journal.pone.0106608.g003
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coupled (R,S)-fenoterol isoforms (Fig. 1C & 2A); this should not
occur if the PTX effect was dependent upon receptor activity,
since b2ARs stimulated by (R,R)-fenoterol have been shown to
only activate Gs [29,39]. (2) PTX treatment amplified forskolin-
evoked cAMP accumulation and increased the potency of forskolin
to evoke an inotropic response (Fig. 3A,B). Responses to forskolin,
being a direct activator of AC [40], should not have been
enhanced by inactivation of Gi; and (3) PTX treatment revealed
intrinsic AC activity upon basal responses only after inhibition of
PDE3 and 4, whereas inverse agonists at muscarinic receptors and
adenosine receptors were without effect after PDE3 and 4
inhibition (Fig. 4A,B). This indicates that PDE3 and 4 inhibition,
even in the presence of the bAR inverse agonist timolol, increased
cAMP levels in PTX-treated tissue sufficiently to produce an
inotropic response (Fig 4A,B,C). If constitutively active Gs-coupled
receptors were mediating this effect, an inotropic response should
have occurred after PDE3 and 4 inhibition alone in the absence of
PTX treatment. Further, PDE3 and, at least in the rat ventricle,
PDE4 activity (Fig. 4A,B; [41]) normally degrades low basal levels
of cAMP, maintaining basal contractile force. These data highlight
the necessity to remove the tonic inhibition of Gi upon AC prior to
PDE inhibition to allow for the enhanced cAMP signal to be
transduced into a functional response. We propose that PTX
removes an intrinsic inhibition of Gi upon AC that is independent
Figure 4. Effect of PTX upon PDE3 and PDE4 inhibitor-induced cAMP accumulation and inotropic response. (A) Effect of simultaneous
inhibition of PDE3 (cilostamide, 1 mM) and PDE4 (rolipram, 10 mM) to evoke an inotropic response in left ventricular strips in control (open bars) and
after PTX pre-treatment (solid bars) in the presence of timolol (1 mM). Basal force was (in mN/mm2): control: 3.360.4; PTX: 3.160.3. (B) Effect of PTX,
bAR inverse agonist timolol (1 mM), non-selective muscarinic inverse agonist atropine (1 mM) or non-selective adenosine receptor inverse agonist CGS
15943 (1 mM) upon PDE3 (cilostamide, 1 mM) and PDE4 (rolipram, 10 mM)-evoked cAMP accumulation. Basal cAMP accumulation (in pmol/mg
protein): timolol control: 4.860.6 (n = 7). (C) Representative traces showing inotropic responses (mN) evoked by inactivation of PDE3 and 4
simultaneously (1 mM cilostamide and 10 mM rolipram) in left ventricular strips of saline-treated control (left) and after PTX pre-treatment (right) in the
presence of 1 mM timolol and 0.1 mM prazosin. Isoproterenol (100 mM displacing timolol) was given to demonstrate that an inotropic effect could be
elicited through bARs. Data are mean 6 SEM. * P,0.05 PTX vs. control, unpaired t-test; ** P,0.05 vs. timolol, One-way ANOVA with Bonferroni
adjustment for multiple comparisons.
doi:10.1371/journal.pone.0106608.g004
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of Gi-coupled receptors. That neither the inverse agonist atropine
(muscarinic M2) nor the non-selective adenosine receptor antag-
onist CGS 15943, alone or in combination, elicits effects similar to
PTX (Fig. 4B, Fig. S1) indicates that PTX does not simply remove
the effect of constitutively active Gi-coupled receptors.
Gi has a propensity to be in a spontaneously active
conformation
There is a good basis indicating that Gi has receptor-
independent activity. Lutz et al. [26] reported that in sarcolemmal
membranes from failing human myocardium, Gi rapidly released
GDP in a time- and temperature-dependent manner. When
GDPbS was used in place of GDP to hold Gi in the inactive state,
AC activity increased, suggesting relief of tonic inhibition. This
effect was replicated by Mn2+ or high Mg2+, which prevent AC
inhibition by Gi. The authors suggest that AC was inhibited by an
empty but apparently active Gi (even in the absence of activating
GTP), further highlighting the inhibitory potential of presumably
inactivated Gi. [26].
Further, Piacentini et al. [42] reported that the synthetic GTP
analogue Gpp(NH)p had no effect on basal AC activity. With the
Gs:Gi ratio ranging from ,1:10 to 1:40 [43,44], Gi would be the
predominant G protein activated under these conditions. Since
AC may already be maximally inhibited by spontaneously active
Gi, it is expected that no additional effect of Gpp(NH)p is seen.
However, when the stable GDP analogue GDPbS was used, basal
AC activity increased, presumably through relief of tonic Gi
inhibition. Under this condition, subsequent addition of Gpp
(NH)p caused inhibition of AC, presumably through competition
with GDPbS [42]. Thus, AC inhibition could be relieved by
introduction of synthetic GDP-analogues and re-introduced by
synthetic GTP-analogues, providing further support for receptor-
independent Gi intrinsic activity.
Regulators of G protein signalling (RGS) are GTPase-acceler-
ating proteins that promote rapid GTP hydrolysis and conse-
quently inhibit signal transduction by inactivating G proteins and
returning them to the GDP-bound heterotrimeric state. The effect
of mutated, RGS-insensitive Gai2 has been studied in cardiomy-
Figure 5. Possible mechanisms mediating the receptor-independent role of Gi in regulating basal AC activity. (A) bc-sink hypothesis: In
the absence of PTX (top panel), spontaneously active Gi dominates, inhibiting basal AC activity and maintaining low cAMP levels which are incapable
of eliciting an inotropic response even after inhibition of PDE3 and 4 (inhibition marked by X). After PTX treatment (bottom panel), Gi is not only
inactivated (through ADP-ribosylation, marked by X) removing its spontaneous intrinsic inhibition upon AC, but also sequesters a large proportion of
the shared Gbc pool. This indirectly increases the proportion of receptor-independent spontaneously active Gs, leading to increased basal AC activity
and cAMP that is normally readily degraded by PDE3 and 4. However, inhibition of PDE3 and 4 (marked by X) allows for translation of this cAMP
increase into an inotropic response (see Fig. 4A). The net result is a shift from predominantly spontaneous Gi activity towards Gs activity, increasing
basal AC activity and promoting activation of AC and positive inotropic effects of all inotropic agents working through increased cAMP signalling. (B)
NDPK-hypothesis: In the absence of PTX (top panel), NDPK-activation of Gi dominates due to excess of Gi protein levels over Gs, resulting in low cAMP
production readily degraded by PDE3 and 4. In the presence of PTX (bottom panel), Gi is inactivated by permanent ADP-ribosylation (marked by X).
Thus, NDPK B could predominantly activate Gs, leading to both increased basal contractile force and cAMP accumulation that becomes revealed after
PDE3 and 4 inhibition (marked by X).
doi:10.1371/journal.pone.0106608.g005
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ocytes derived from embryonic stem cells [45] and mice
homozygous for the mutated, RGS-insensitive Gai2 [46], provid-
ing a model for studying active Gi. Interestingly, basal inotropic
and lusitropic responses were reduced by ,10% in these mice
compared to wildtype [46]. Also, Gs-dependent stimulation of
beating rate by the b2-AR agonist procaterol was nearly abolished
in foetal RGS-insensitive Gai2-cardiomyoctes via a PTX-sensitive
mechanism, further indicating that Gi exerts tonic inhibition on
AC [45].
Chen-Goodspeed et al. [47] reported that human AC5 has high
basal activity when expressed in Sf9 cell membranes, which was
concentration-dependently inhibited by GTPcS-activated Gai.
AC6 basal activity was low, but could be inhibited by Gai if
previously activated with GTPcS-Gas [47]. Thus, the two most
common AC isoforms in the heart have the tendency to be
spontaneously active, providing a substrate for opposition by
intrinsic Gi activity.
In addition, data suggest that AGS proteins (activators of G
protein signalling) may promote G protein activation by either
directly acting as a guanine nucleotide exchange factor or by
interfering with subunit association/dissociation/trafficking (both
dependent and independent of nucleotide exchange) preventing
heterotrimeric Gabc formation [48]. Together, these effects of
AGS could potentially provide another plausible mechanism for
mediation of receptor-independent Gi activity. Consistent with this
hypothesis, Graham et al. [49] have shown that AGS1, which is
selective for Gai2 and Gai3, inhibited cAMP accumulation evoked
by constitutively active Gs or forskolin in 293T cells [49].
Does PTX treatment shift the balance of intrinsic Gi and
Gs activity upon AC towards Gs?
Although the current data support the hypothesis that Gi exerts
intrinsic receptor independent inhibition upon spontaneous AC
activity, the mechanism is still unknown. Further, we cannot
completely rule out the possibility that PTX treatment removes an
unknown constitutively active Gi-coupled receptor. Despite these
limitations, it is reasonable to hypothesize that the ratio of Gs:Gi
has important implications for the regulation of basal AC activity.
As reported here, a minimum of 80-90% ADP-ribosylation of Gi
was necessary to reveal functional effects of PTX treatment in our
models. Under this scenario, the normal reported ratio of Gs:Gi of
,1:10 to ,1:40 would be altered to ,1:1 to ,1:4, giving Gs more
favourable terms to compete for binding to AC. This is consistent
with Lutz et al. [26] who suggested that the AC system may be
designed to operate from a predominantly off position (high
intrinsic Gi activity), as both basal AC activity and Gs-coupled
receptor activation would be enhanced by PTX inactivation of Gi.
The mechanism that mediates these effects of PTX treatment
remains to be determined.
It has recently been reported that Gs and Gi compete for an
apparently limited pool of bc [50]. Based on this finding, it is
possible that as inactive GDP-bound Gi becomes ADP-ribosylated
by PTX, Gi sequesters bc from the total shared pool. Under this
scenario, over time, there will be less bc available for Gs,
consequently increasing the probability of Gs to be in its active
state (GTP-bound) in addition to the corresponding removal of
intrinsically active Gi. A plausible hypothesis would be that Gi acts
as a bc sink. In support, overexpression of bARK-ct, a bc
scavenger, resulted in increased AC stimulation [51]. The net
effect of PTX treatment would be to shift the balance from largely
intrinsic inhibition to a greater intrinsic stimulation upon AC,
thereby sensitising AC and enhancing/amplifying those systems
known to activate AC (Fig. 5A).
Alternatively, based on the findings of Hippe et al. [52], PTX
treatment may shift the ability of endogenous nucleoside
diphosphate kinase B (NDPK B) to activate the Gi and Gs
proteins. NDPK B is a G protein histidine kinase that regulates
cAMP synthesis and cardiomyocyte contractility independent of
GPCRs through the formation of an NDPK B-Gbc complex that
activates G protein through a phosphotransfer from NDPK B to
His-266 in Gb [52]. The phosphate is then transferred onto GDP,
and the resultant GTP leads to receptor-independent G protein
activation [52–54]. In the normal state, due to the excess of Gi
over Gs, NDPK B would predominantly activate Gi and the
stimulatory effects of Gs upon basal cAMP generation may be
neutralized [52]. After PTX treatment, Gi is inactivated by
permanent ADP-ribosylation. Thus, NDPK B would predomi-
nantly activate (potentiate) Gs activity leading to both increased
basal contractile force and cAMP accumulation that becomes
revealed after PDE3 and 4 inhibition (Fig. 5B). That we also
observe enhancement of other cAMP signalling inotropes and
forskolin is consistent with this hypothesis. To this end, experi-
ments are currently underway to test both hypotheses, and should
provide greater clarity of the mechanism behind intrinsic receptor-
independent inhibitory activity of Gi upon AC.
Supporting Information
Figure S1 Effect of PTX, bAR inverse agonist timolol
(1 mM), non-selective muscarinic inverse agonist
atropine (1 mM) or non-selective adenosine receptor
inverse agonist CGS-15943 (1 mM) upon PDE3 (cilosta-
mide, 1 mM) and PDE4 (rolipram, 10 mM)-evoked ino-
tropic response. Data are mean 6 SEM. * P,0.05 vs. PTX,
One-way ANOVA with Bonferroni post test adjustment for
multiple comparisons.
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